The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells
Autor: | Antonio Paz, Luis Delgado-Pérez, Rafael Franco, Juan Muñóz, Antonio Campos-Caro, Esther Ocaña, José A. Brieva |
---|---|
Rok vydání: | 2007 |
Předmět: |
Male
medicine.medical_specialty Receptors CXCR3 Chronic lymphocytic leukemia Gene Rearrangement B-Lymphocyte Heavy Chain Immunoglobulin Variable Region Kaplan-Meier Estimate Biology CXCR3 Statistics Nonparametric Chemokine receptor immune system diseases hemic and lymphatic diseases Internal medicine Biomarkers Tumor medicine Humans Aged Proportional Hazards Models Membrane Glycoproteins Hematology Gene Expression Regulation Leukemic Gene rearrangement Prognosis medicine.disease ADP-ribosyl Cyclase 1 Leukemia Lymphocytic Chronic B-Cell Survival Analysis Neoplasm Proteins Leukemia medicine.anatomical_structure Tumor progression Immunology Cancer research Female Receptors Chemokine Somatic Hypermutation Immunoglobulin Bone marrow Follow-Up Studies |
Zdroj: | Haematologica. 92:349-356 |
ISSN: | 1592-8721 0390-6078 |
DOI: | 10.3324/haematol.10649 |
Popis: | Background and Objectives Chemokine receptors are involved in tumor progression and several of these receptors, including CXCR3, are expressed by chronic lymphocytic leukemia (CLL) B cells. This study was aimed to examine a possible relationship between CXCR3 expression in CLL and the clinical evolution of the disease. Design and Methods Using flow activated cell sorting (FACS), we analyzed the level of expression of CXCR3 on blood CLL B cells from 76 consecutive patients. The results were correlated with CD38 expression, IgV H gene status and clinical outcome. Results CXCR3, measured as mean fluorescence intensity (MFI), was unimodally expressed by blood tumor cells at various levels (range, 3.5 to 232.3) but levels within individual patients were remarkably stable over time. Low CXCR3 expression by CLL B cells was strongly associated with Rai disease stages III and IV ( p |
Databáze: | OpenAIRE |
Externí odkaz: |